In a crucial vote. a panel of outside advisers to the Food and Drug Administration unanimously voted that the benefits of the drug made from cannabis outweigh its risk. (Photo: Bloomberg)
(Bloomberg) –U.S. drug regulators are edging closer to approving the first-ever medicine derived from a marijuana plant, an experimental epilepsy treatment developed by GW Pharmaceuticals Plc.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
